Gan & Lee Pharmaceuticals. (SHA: 603087)

Market Cap	23.59B
Revenue (ttm)	2.69B
Net Income (ttm)	504.82M
Shares Out	597.09M
EPS (ttm)	0.87
PE Ratio	45.42
Forward PE	27.63
Dividend	0.20 (0.51%)
Ex-Dividend Date	Jun 18, 2024

Volume	3,985,816
Open	40.92
Previous Close	40.10
Day's Range	39.45 - 40.92
52-Week Range	32.10 - 62.90
Beta	1.58
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2024

About Gan & Lee Pharmaceuticals.

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. The company’s products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro and lispro mix 75/25 injection; Prandilin 25, an insulin lispro injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection. It also offers GanleePen, an insulin injection device; ...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1998
• Employees: 4,482
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603087